We examined the basis of the all or none dierence in inducing melanocytic tumor development among three transgenic mouse lines (304, 192 and 242) to which the same promoter-enhancer (metallothionein-I) and oncogene (ret) were introduced. We initially demonstrated that both skin melanosis and Ret protein expression in skin, thymus and brain ®rst became detectable before or immediately after birth in the mice of the tumor developing lines (304 and 192), whereas they became detectable a few days after birth in the mice of the nontumor developing line (242) by Western blotting and immunohistochemical analysis. Interestingly, the Ret protein expression in skin developed rapidly after birth as a burst with peak levels on 0.5 ± 1.5 day newborns of lines 304 and 192 and on 7.0 ± 7.5 day-old mice of line 242. The levels of autophosphorylation of Ret kinase in skin were, however, invariable among these three transgenic mouse lines. The mice of line 242, but not those of lines 192 and 304, responded to Ret protein immunization by increased antigen-dependent lymphocyte proliferation and T-cell-mediated tumor growth suppression in vitro. Furthermore, ret-transgenic mice of line 242, but not line 304, rejected the subcutaneously transplanted tumors that had originally developed in a mouse of line 304. These results suggest that whether oncogene product-speci®c-tolerance is established or not to antitumor immunity may be decided by the dynamics of ret oncogene expression before and after delivery and this is the primary factor determining development or non-development of melanoma.
Despite a number of relevant earlier studies, it remains to be determined whether the potential anti-tumor immunity targeting oncogene products would play an important role in immune surveillance of tumors. In cases of viral oncogene products such as simian virus (SV40) large T antigen (Campbell et al., 1983; Schrmberk et al., 1992; Tevethia et al., 1980) , E1A protein of adenovirus (Kast et al., 1989) and papilloma type 16 nucleoprotein E7 (Chen et al., 1991) , it is acknowledged that the anti-tumor immunity targeting these antigens could prevent growth of the tumor expressing these oncogenes which are transplanted into syngeneic animals. Moreover, Faas et al. (1987) demonstrated that SV40 large T antigen-speci®c tolerance was established in a line of SV40-transgenic mice, in which tumors frequently develop, but not in a line free from frequent tumor development. They suggested, but did not experimentally prove, that the time of onset of the viral oncogene expression may greatly aect the mode of immunological recognition of the antigen. Very little knowledge is available about the ability of cellular oncogene products to protect animals from tumor development. All cellular oncogenes bearing any sequence modi®cation during tumor development are potentially immunogenic, although rather rare examples have been reported to actively trigger anti-tumor immunity for tumor eradication. These include mutated ras (Jung and Schluesener, 1991) and p53 (Yanuck et al., 1993) , which could be recognized by CTL. Nevertheless, there is still no direct evidence that any of these cellular oncogene products play as crucial a role as viral oncogene products in the immunological surveillance of tumor at the early stage of tumor development in human and animals.
Previously, we established three lines (304, 192 and 242) of transgenic mice by introducing the human cellular oncogene (ret) fused to the mouse metallothionein-I (MT) promoter-enhancer (Iwamoto et al., 1991) . In all of these three lines of MT/ret transgenic mice, systemic severe skin melanosis developed. Skin melanocytic tumors, however, developed in 100% of MT/ret transgenic mice of lines 304 and 192, but never in the mice of line 242. In our earlier studies on Em/rettransgenic mice, in which pre-B lymphoma developed, we provided evidence that the ret-speci®c immunity which was successfully induced by injections of histocompatible mice with appropriately xenogenized pre-B lymphoma cells from the Em/ret transgenic mice, speci®cally suppressed the growth of the Em/ret transgenic mouse-derived pre-B lymphoma and MT/ ret transgenic mouse (line 304)-derived melanocytic tumor, but not Em/myc transgenic mouse-derived pre-B lymphoma (Ichihara et al., 1995) . The ret-speci®city of this immunity was also con®rmed in in vitro tumor cell killing by eector cells collected from the immunized mice (Dai et al., 1994; Ichihara et al., 1995) . In this study, by using the lines of MT/ret transgenic mice with dierential phenotypes for tumor development, we tested the possibility that the immunity targeting oncogene product, which might vary with the time of onset of oncogene product expression, could be crucially involved in the surveillance of primarily developing tumors. The results demonstrate a surprising burst of Ret protein expression which peaks soon after birth and coincides with the quick development of skin melanosis. An apparently small variation with the time of onset of this burst has been shown to be associated with the all or none dierence for establishment of tolerance to the oncogene product and tumor development.
We examined the time course of the skin melanosis development in the MT/ret transgenic mice, and found de®nite dierences in the time of its onset among the three lines. In line 304, melanosis developed ®rst on the ear skin of 18.5 ± 19.0 day embryos, and then on the whole body skin of 0.0 ± 0.5 day newborns, which thereafter increased rapidly, reaching a plateau level on skin of 2.0 ± 2.5 day-old mice ( Figure 1a ). On the skin of mice of line 192, melanosis did not exist just after delivery, but developed rapidly for several hours after delivery, reaching a plateau level by 2.0 ± 2.5 days after birth (Figure 1b) . On the skin of the mice of line 242, however, melanosis began to develop as late as 2.5 ± 3.0 days after birth, reached a plateau by 6.5 ± 7.0 days after birth (Figure 1c) , and was almost as extensive as that attained in other lines.
Next, we examined the kinetics of the levels of Ret protein expression in skin from MT/ret transgenic mice of lines 304, 192, and 242, compared with those from non-transgenic mice. In line 304, production of a de®nite amount of Ret protein in skin was already demonstrated in 18.5 ± 19.0 day embryos, which further increased after birth and peaked in 0.5 day-old newborns (Figure 2a, left panel) . Surprisingly, the level of Ret protein expression in skin thereafter declined with aging, suggesting a delivery-linked temporal burst of the oncogene expression. De®nite Ret protein expression in skin from the 0.0 ± 0.5 dayold transgenic mouse of line 304 was con®rmed by immunohistochemical analysis, which demonstrated Ret protein positive cells mainly in the dermis of the transgenic mouse (Figure 3b ), but not in that of the non-transgenic control litter mouse ( Figure 3a) . In line 192, Ret protein expression had almost burst in skin of 1.0 ± 1.5 day-old newborns following the low-level onset in skin of 0.0 ± 0.5 day-old newborns ( Figure  2b ). The level of Ret protein expression in the skin of mice of this line also declined with aging after this burst. In line 242, Ret protein was not produced in any detectable amounts in skin of 1.0 ± 1.5 day-old newborns, and was ®rst demonstrable in a small amount in 2.5 ± 3.0 day-old newborns ( Figure 2c ). The Ret protein expression in this line, however, burst in skin of 6.5 ± 7.0 day-old newborns ( Figure 2c ) and declined thereafter with aging (not shown). The time of onset of the demonstrated burst of Ret protein expression in the three lines of transgenic mice well corresponded with that of skin melanosis in those mice (Figure 1 ). Again, in thymus and brain, de®nite Ret protein expression on 0.0 ± 0.5 day-old transgenic mice of lines 304 and 192 was observed, and declined thereafter with aging (Figure 2a and b, middle and right panels). However, in line 242, Ret protein was not produced in any detectable amounts in thymus and brain of 0.0 ± 0.5 day-old newborns, and was demonstrable in 6.5 ± 7.0 day-old newborns ( Figure 2c ). Ret protein expression in thymus from the 0.0 ± 0.5 day-old transgenic mouse of line 304 was also con®rmed by immunohistochemical analysis. Ret protein positive cells existed here and there, forming colonies in thymus of the transgenic mouse (Figure 3d ), but fewer in that of the nontransgenic control litter mouse (Figure 3c ). Ret protein expression as observed in the three lines of MT/ret transgenic mice was almost undetectable in skin, thymus and brain of the age-matched non-transgenic control mice under the same condition as indicated in Figures 2 and 3 (data not shown) . In addition, in liver, Ret protein expression could not be detected in either the three lines of the MT/ret transgenic mice or the non-transgenic control mice (data not shown). In order to rule out any qualitative variation in the Ret protein among these three lines, we comparably measured the autophosphorylation levels of the Ret tyrosine kinase. As shown in Figure 2d , Ret proteins in the skin from lines 304, 192 and 242 were evenly autophosphorylated at the tyrosine, suggesting their functional homogeneity.
The present ®ndings revealing quantitative rather than qualitative dierences in the time course of development of melanosis and Ret protein expression, beg the question: What is the key element determining the all or none incidence of tumor development in the three lines of transgenic mice? One of the established principles in immunology is the switching self-and non-self recognitions of the antigen developing just before or after birth. We therefore examined whether the dierential onsets of a burst of Ret expression in skin could cause a dierence in the Ret protein-speci®c immunological status of the three lines of MT/ret transgenic mice. We immunized 10-week-old nontransgenic BCF-1 mice and transgenic mice of lines 304, 192, and 242 with Ret protein, and examined the antigen (Ret)-dependent T-cell proliferation response in Figure 2 Time course of Ret protein expression in skin, thymus and brain from MT/ret transgenic mice of lines 304, 192, and 242. In (a) (line 304), (b) (line 192) and (c) (line 242), levels of Ret protein expression in indicated tissues (Sk, skin; Th, thymus; Br, brain) from the transgenic mice of dierent ages (F, fetus; N, newborn) were determined by Western blotting with anti-Ret antibody (Takahashi et al., 1993) according to the method described previously (Kato et al., 1994) . In (d) autophosphorylation levels of Ret tyrosine kinase in the skin from the MT/ret transgenic mice of line 304 (0.0 ± 0.5 day-old), 192 (1.0 ± 1.5 dayold), and 242 (7.0 ± 7.5 day-old) were examined by immunoprecipitation with anti-Ret antibody followed by Western blotting with anti-phosphotyrosine antibody (D1; Transduction Laboratories, Lexington, KY, USA) or anti-Ret antibody (D2) vitro using a previously established method (Corradin et al., 1977; Dai et al., 1994) . As expected, spleen cells from non-transgenic BCF1 mice previously immunized with the Ret protein (Figure 4c ), but not those from non-immunized BCF1 mice (Figure 4a ) or BCF1 mice immunized with DE3 bacterial proteins as control of the Ret protein (Figure 4b ), proliferated well in response to the Ret protein added to the cell culture line. On the other hand, the spleen cells from the transgenic mice of lines 304 and 192 immunized with the Ret protein (Figure 4d and e) showed no evidence of proliferation by the same stimulation. The spleen cells from the Ret protein-immunized transgenic mice of line 242 (Figure 4f ), however, showed a level of proliferation response to the Ret protein in vitro as high as those from the non-transgenic BCF1 mice. These results suggested that immunological tolerance to ret oncogene product was established in the transgenic mice of lines 304 and 192, but not in those of line 242.
We next examined whether the Ret protein-induced immunity involves some antitumor immunity to suppress the tumor growth in vitro. As shown in Figure 5 , peritoneal exudate cells (PEC) from the BCF1 mice and line 242 transgenic mice that had been immunized with Ret protein suppressed the growth of Mel-ret cells in vitro. This eect was lost by T-cell elimination from PEC using anti Thy-1 mAb and low toxic complement (Figure 5b1 and b2 ). An additional experiment showed that elimination of macrophages from PEC by incubation on plastic dishes before assay also reduced the anti-tumor activity of PEC (data not shown), suggesting the involvement of Th1-cell immunity whose ultimate eector cells should be Th1-cell-derived cytokines-activated macrophages (Mosmann et al., 1991 ) at the skin developed in all the mice of line 304 (4/4), but not in the mice of line 242 (0/4). These results con®rm that the immune reaction in the MT/ret transgenic mice of line 242 could actually eliminate tumor cells in vivo, possibly recognizing the Ret oncogene product.
The central ®nding of this study was the demonstration of a unique burst of Ret protein expression with dierential onset at the time around delivery in three lines (lines 304, 192 and 242) of MT/ret transgenic mice, which all display extensive melanosis but do (lines 304 and 192) or do not (line 242) develop melanocytic tumors. The dierential onset of the burst of Ret protein expression was well correlated with the onset of melanosis just before or after birth. Interestingly, the slightly earlier onset of the burst of Ret protein expression and melanosis development in lines 304 and 192 compared to line 242 was closely linked to the establishment of immunological tolerance to the Ret antigen that prevents development of antitumor immunity and the phenotype of tumor development. Recent reports of revisiting the classical experiments of Medawar and his colleagues revealed that lymphocytes in newborn mice indeed carry the innate capacity to respond to antigen but are prone to induction of tolerance when newborn mice under 1 day old, carrying only a small number of lymphocytes, are Figure 4 Ability for proliferative response to Ret protein in vitro of splenic lymphocytes from MT/ret transgenic mice of lines 304, 192, and 242 . Ten mg of recombinant ret oncogene product (Ret protein) in complete Freund's adjuvant (CFA) was injected subcutaneously to MT/ret transgenic mice of lines 304, 192 and 242, and non-transgenic BCF1 mice twice at a 10-day interval. After 14 days from the last immunization, spleen cells taken from BCF1 mice, either non-immunized (a) or previously immunized with DE3 bacterial proteins as control (b), or with the recombinant ret oncogene product (c) and transgenic mice of lines 304 (d), 192 (e) and 242 (f) previously immunized with the recombinant ret oncogene product, were cultured in 96-well tissue culture plate at 10 6 cells per well, stimulatd with 0 ± 8 ng of the recombinant ret oncogene product. Their DNA synthesis on day 2 was measured by [ 3 H]thymidine uptake assay by the method described previously . The samples were assayed in triplicate and the results expressed as mean counts per minute (c.p.m.)+s.d. Shown is a representative of four experiments. The values marked *(P50.01) and {(P50.05) are signi®cantly dierent from that of the control with no recombinant ret oncogene product by statistical analysis with the Wilcoxon's matched-pairs signed-rank test exposed to a relatively large amount of antigen. A burst of Ret protein expression soon after birth, which we demonstrated on skin, thymus and brain of lines 304 and 192 transgenic mice, would be an event very eective for inducing tolerance of lymphocytes in this antigen. A slight delay in the onset of the burst of Ret protein expression probably became ineective for inducing tolerance to the already expanded number of lymphocytes.
The reason why the Ret protein expression burst soon after birth in MT/ret transgenic mice is not known, but might be because of a sudden change in environmental stress in the newborn mice. Whatever the underlying mechanism is, the demonstrated burst of protein expression soon after birth could be a mechanism eective for self recognition of cellular proteins by newborn animals. The result that the level of Ret protein expression declined with aging after the burst suggests a mechanism to downregulate the protein expression after a burst. Furthermore, the fact that the dynamics of Ret protein expression in skin and brain corresponded well with the dynamics in the central immune system (thymus) would suggest that the quantity and dynamics of cellular oncogene expression during the critical period to recognize self or non-self have a great eect on the establishment of tolerance to the oncogene product, which ultimately in¯uences the immune surveillance of tumors targeting cellular oncogene products. , which were derived from melanocytic tumor of a MT/ret transgenic mouse of line 304 (Taniguchi et al., 1992) , were incubated in 96-well tissue culture plates in the presence or absence of PEC (5610 5 ) and the anti-tumor eect of PEC to suppress growth of Mel-ret cells was examined by both [ 
